Categories Earnings, Health Care
Dynavax Technologies Corporation (NASDAQ: DVAX): Q4 2019 Earnings Snapshot
— Biopharmaceutical company Dynavax Technologies Corporation (NASDAQ: DVAX) reported a net loss of $36.8 million $0.44 per share for the fourth quarter of 2019, vs. $0.33 per share loss expected.
— Total sales more than doubled year-over-year to $10.57 million, vs. $11.96 million expected
— Research and development expenses dropped to $12.3 million in the fourth quarter from $22.9 million last year
— Established research collaboration with the University of Queensland and the Coalition for Epidemic Preparedness to develop coronavirus vaccine
— Appointed Ryan Spencer chief executive officer and to the board of directors; named David Novack president and chief operating officer
— Expects HEPLISAV-B net product revenue to increase to $55-$62 million in fiscal 2020
— On track to release interim data from ongoing study of HEPLISAV-B in hemodialysis patients in the first quarter
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
GIS Earnings: All you need to know about General Mills’ Q1 2025 earnings results
General Mills, Inc. (NYSE: GIS) reported its first quarter 2025 earnings results today. Net sales decreased 1% year-over-year to $4.8 billion. Organic sales were down 1%. Net earnings attributable to
Guardian Pharmacy seeks to raise up to $108 mil in US IPO
Joining the wave of healthcare IPOs this year, amid Fed rate cut expectations, Guardian Pharmacy Services, Inc. is preparing to go public. In a statement filed with the Securities and
Earnings Preview: Will Micron (MU) maintain recovery momentum in Q4?
After recovering from a rough patch, Micron Technology Inc. (NASDAQ: MU) is preparing to report fourth-quarter results next week, even as the market keeps a close watch on the event
